Impact of expert pathologic review of thymic epithelial tumours on diagnosis and management in a real-life setting: A RYTHMIC study.


Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
01 2021
Historique:
received: 05 09 2020
revised: 07 11 2020
accepted: 12 11 2020
pubmed: 15 12 2020
medline: 24 4 2021
entrez: 14 12 2020
Statut: ppublish

Résumé

Classification of thymic epithelial tumours (TETs) is known to be challenging; however, the level of discordances at a nationwide level between initial and expert diagnosis and their clinical consequences are currently unknown. RYTHMIC is a national network dedicated to the management of TET based on initial histological diagnosis, followed by an additional expert review of all cases. Our aim was to evaluate the discordances between initial and expert diagnoses and whether they would have led to different clinical management. We conducted a retrospective analysis of the cohort of patients discussed at RYTHMIC tumour board from January 2012 to December 2016. Assessment of disagreement was made for histological typing and for staging. The discordances were classified as major or minor based on whether they would have changed or not the proposed therapeutic strategy, respectively. Follow-up of the patients with major discordances was conducted until December 2018. Four hundred sixty-seven patients were reviewed, and 183 (39%) discordances were identified either related to histological subtype (132) and/or stage (72). Major discordances were identified in 27 patients (6%). They included 16 patients with TET for whom treatment recommendation based on the central review would have been post-operative radiotherapy, whereas it had not been the case. However, follow-up did not show any progression among the 15 patients with high-grade histology and/or stage resected thymomas. On the other hand, among the remaining 11 patients including 7 with a diagnosis other than TET, the overall management or follow-up would have been completely different with the expert diagnosis. Our real-life cohort reveals a high level of discordances considering TET diagnosis and supports expert review for optimal clinical management.

Sections du résumé

BACKGROUND
Classification of thymic epithelial tumours (TETs) is known to be challenging; however, the level of discordances at a nationwide level between initial and expert diagnosis and their clinical consequences are currently unknown. RYTHMIC is a national network dedicated to the management of TET based on initial histological diagnosis, followed by an additional expert review of all cases. Our aim was to evaluate the discordances between initial and expert diagnoses and whether they would have led to different clinical management.
PATIENTS AND METHODS
We conducted a retrospective analysis of the cohort of patients discussed at RYTHMIC tumour board from January 2012 to December 2016. Assessment of disagreement was made for histological typing and for staging. The discordances were classified as major or minor based on whether they would have changed or not the proposed therapeutic strategy, respectively. Follow-up of the patients with major discordances was conducted until December 2018.
RESULTS
Four hundred sixty-seven patients were reviewed, and 183 (39%) discordances were identified either related to histological subtype (132) and/or stage (72). Major discordances were identified in 27 patients (6%). They included 16 patients with TET for whom treatment recommendation based on the central review would have been post-operative radiotherapy, whereas it had not been the case. However, follow-up did not show any progression among the 15 patients with high-grade histology and/or stage resected thymomas. On the other hand, among the remaining 11 patients including 7 with a diagnosis other than TET, the overall management or follow-up would have been completely different with the expert diagnosis.
CONCLUSION
Our real-life cohort reveals a high level of discordances considering TET diagnosis and supports expert review for optimal clinical management.

Identifiants

pubmed: 33316754
pii: S0959-8049(20)31334-4
doi: 10.1016/j.ejca.2020.11.011
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

158-167

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.

Auteurs

Thierry J Molina (TJ)

Department of Pathology, AP-HP, INSERM U1163, Institut Imagine, Hôpital Universitaire Necker-Enfants-Malades, Université de Paris, Paris, France. Electronic address: thierry.molina@aphp.fr.

Maria V Bluthgen (MV)

Department of Cancer Medicine, Gustave Roussy, Villejuif, France.

Lara Chalabreysse (L)

Department of Pathology, Groupement Hospitalier Est, Hospices Civils de Lyon, France.

Vincent T de Montpréville (VT)

Department of Pathology, Institut d'oncologie thoracique, Hôpital Marie-Lannelongue, Le Plessis-Robinson, France.

Anne de Muret (A)

Department of Pathology, CHU de Tours, France.

Romain Dubois (R)

Institute of Pathology, CHU de Lille, France.

Véronique Hofman (V)

University Côte d'Azur, Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Pasteur Hospital, Biobank, 0033-00025, Nice, France.

Sylvie Lantuejoul (S)

Department of BioPathology, CHU de Centre Léon Bérard, Lyon, and Grenoble Alpes University, Grenoble, France.

Cécile le Naoures (C)

Department of pathology, CHU Rennes, Rennes, France.

Audrey Mansuet-Lupo (A)

Department of Pathology, AP-HP, INSERM U1138, Centre de Recherche des Cordeliers, Hôpital Universitaire Cochin, Université de Paris, Paris, France.

Marie Parrens (M)

Department of Pathology, CHU de Bordeaux, INSERM U1053, Université de Bordeaux, 146 rue Léo Saignat, 33076, Bordeaux, France.

Nicolas Piton (N)

Rouen University Hospital, Department of Pathology, F 76 000, Rouen, France.

Isabelle Rouquette (I)

Department of Pathology, CHU Toulouse Oncopole, 1 avenue I Joliot Curie, 31059, Toulouse, France.

Véronique Secq (V)

Department of Pathology, Hôpital Nord, AP-HM, Marseille, France.

Nicolas Girard (N)

Université de Lyon, Université Claude Bernard Lyon 1, Hospices Civils de Lyon, Lyon, France; Institut Curie, Paris, France.

Alexander Marx (A)

Institute of Pathology, Mannheim Medical University, Heidelberg University, Mannheim, Germany.

Benjamin Besse (B)

Department of Cancer Medicine, Gustave Roussy, Villejuif, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH